Bioclinica acquires VC-backed Clinverse

By Iris Dorbian — 3 weeks ago

Bioclinica has acquired Durham, North Carolina-based Clinverse, a provider of automated financial management technology solutions for clinical trials. No financial terms were disclosed. Clinverse’s backers included Edison Partners and Hatteras Venture Partners.

Continue

ORIG3N raises $12.5 mln

By Luisa Beltran — 2 months ago

ORIG3N Inc. said Wednesday that it closed a $12.5 million Series A financing co-led by Hatteras Venture Partners and Syno Capital. Also participating in the round was new investor, DEFTA Partners, and existing investors, Harris & Harris Group Inc., LabCorp, MGC Venture Partners and KTB-KORUS Fund. ORIG3N is a biotechnology company that is developing treatments for rare and genetically inherited diseases.

Continue

Qvella scores $20 mln Series A

By Iris Dorbian — 3 months ago

Canadian molecular diagnostics company Qvella has secured $20 million in Series A funding. RA Capital Management and Whitecap Venture Partners led the round with participation from other investors that included Hatteras Venture Partners and Sands Capital Ventures. According to the company, the capital infusion will be used for personnel hiring and product development.

Continue

Patient engagement platform Medfusion reels in $3 mln

By Iris Dorbian — 5 months ago

Cary, North Carolina-based patient engagement platform Medfusion Inc has raised $3 million in funding. The investors were Bull City Venture Partners and Hatteras Venture Partners. In conjunction with the funding, David Jones of Bull City Venture Partners and John Crumpler of Hatteras Venture Partners have been appointed to Medfusion’s board.

Continue

Malin Corp invests in Hatteras Venture Partners and Jaan Health

By Iris Dorbian — 6 months ago

Irish global life sciences company Malin Corp has agreed to invest $15 million in North Carolina-based Hatteras Venture Partners, a venture firm that focuses on early-stage companies in life sciences. The investment could hike up to $20 million “depending on a number of factors.” Also, Malin has agreed to invest up to $1 million in New York-based healthcare mobile tech company Jaan Health. In addition to the investments, Malin CEO Adrian Howd will become the company’s chief investment officer while remaining on the company’s board of directors. And, Kelly Martin, who’s currently on Malin’s board of directors, will step into the Malin CEO position.

Continue

NuSirt takes in $6 mln Series C

By Iris Dorbian — 9 months ago

Nashville-based NuSirt Biopharma, which focuses on helping people with chronic metabolic diseases, has secured $6 million in Series C funding. The investors included Hatteras Venture Partners, Mountain Group Partners and TriStar Technology Ventures.

Continue

Spyryx Biosciences rakes in $18 mln Series A

By Iris Dorbian — 9 months ago

Research Triangle Park, North Carolina-based Spyryx Biosciences, which develops treatments for respiratory diseases, has raised $18 million in Series A funding. The investors were Canaan Partners, Hatteras Venture Partners and 5AM Ventures. In conjunction with the funding, Dr. Tim Shannon, general partner of Canaan, has been named chairman of Spyryx’s board of directors. Also, Dr. Christy Shaffer, managing director of Hatteras Discovery at Hatteras and Dr. Brian Daniels, venture partner of 5AM, have been added to Spyryx’s board of directors.

Continue

PhaseBio Pharmaceuticals picks up $40 mln Series C

By Iris Dorbian — 11 months ago

Malvern, Pennsylvania-based PhaseBio Pharmaceuticals Inc, which is focused on developing treatments for metabolic and specialty cardiopulmonary disorders, has secured $40 million in Series C funding. AstraZeneca led the round with participation from New Enterprise Associates, Hatteras Venture Partners, Johnson & Johnson Innovation – JJDC and Fletcher Spaght Ventures. In addition to the funding, Dr. Michael Gutch of AstraZeneca has been added to PhaseBio’s board of directors while Donald Dwyer, also of AstraZeneca, has become a board observer.

Continue

LTI picks up $20 mln Series A

By Iris Dorbian — 1 year ago

Cambridge, Massachusetts-based Lysosomal Therapeutics Inc, which develops molecules to treat neurodegenerative diseases, has closed $20 million in Series A funding. The backers in this round included Atlas Venture, Hatteras Venture Partners, Lilly Ventures, Sanofi-Genzyme BioVentures, Roche Venture Fund, Partners Innovation Fund and Orion Equity Partners.

Continue

Clinipace picks up $50 mln

By Iris Dorbian — 1 year ago

Morrisville, North Carolina-based Clinipace Worldwide, a digital clinical research organization, has raised $50 million in funding. Virgo Investment Group led the round with participation from other investors that included Crestline Investors, Morgan Stanley Expansion Capital, Hatteras Venture Partners, Harbert Venture Partners and Mario Family Funds. Perella Weinberg Partners served as an advisor on the transaction.

Continue

Viamet Pharma raises $60 mln

By Luisa Beltran — 1 year ago

Viamet Pharmaceuticals Holdings said Tuesday it closed a $60 million Series D financing provided by Brandon Point Industries Ltd. working with Woodford Investment Management. Current investors includes Novartis Venture Fund, Lilly Ventures, Hatteras Venture Partners, Intersouth Partners, Lurie Holdings and Astellas Venture Management. Durham, N.C.-based Viamet Pharma develops antifungal agents using a metalloenzyme medicinal chemistry platform.

Continue

Clearside Biomedical picks up $16 mln Series B

By Iris Dorbian — 1 year ago

Clearside Biomedical said Monday that it has raised $16 million in Series B financing. The investors included RusnanoMedInvest, Hatteras Venture Partners, Santen Pharmaceuticals Co. Ltd., Mountain Group Capital and Georgia Research Alliance Venture Fund. Headquartered in Alpharetta, GA, Clearside Biomedical is a clinical-stage biopharmaceutical firm focused on treating eye diseases.

Continue

Atlas Venture leads seed round for Lysosomal Therapeutics

By Iris Dorbian — 2 years ago

Lysosomal Therapeutics has secured $4.8 million in seed funding. Atlas Venture led the round with participation from Hatteras Venture Partners, Lilly Ventures, Sanofi-Genzyme BioVentures, Roche Venture Fund, Partners Innovation Fund and Orion Equity Partners. Headquartered in Cambridge, Mass., Lysosomal Therapeutics develops molecules to be used to treat neurodegenerative diseases.

Continue

Santen and Clearside Biomedical Enter into Research and Financial Pact

By Connie Loizos — 3 years ago

Santen, an Emeryville, Calif.-based subsidiary of Japan-based Santen Pharmaceuticals, has entered into a research collaboration agreement with Clearside Biomedical of Alpharetta, Georgia, a company in which Santen, along with other financial backers, is also making an investment. Specifically, Clearside’s “microinjection platform,” which provides access to the retina and choroid, just attracted $7.9 million in fresh funding from Santen, Mountain Group Capital, Hatteras Venture Partners, Georgia Research Alliance Fund, and Kenan Flagler Business School Private Equity Fund.

Continue